Objective: Cytoreductive surgery (CRS) is the most important treatment method that increases survival in advanced-stage ovarian cancer (OC) patients. However, complications after CRS are seen as a significant cause of morbidity and mortality. Preoperative risk assessment of patients is of great importance. In recent years, inflammatory markers have been the subject of many studies evaluating malignancy and surgical outcomes. Ca125, Neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), Monocyte–lymphocyte ratio (MLR), systemic inflammation index (SII), and systemic inflammatory response index (SIRI) stand out as prognostic and predictive tools in malignancies. This study aims to evaluate the preoperative inflammatory markers in patients who underwent CRS for advanced-stage epithelial ovarian cancer and to investigate the predictive power of postoperative complications. Materials and Methods: This retrospective study examines patients who underwent CRS due to advanced-stage epithelial OC at Sakarya University Training and Research Hospital between 2014 and 2023. Postoperative complications of the patients were graded according to the Clavien–Dindo classification (CDC); Ca125, NLR, PLR, SII, SIRI and MLR values were calculated using preoperative laboratory data, and the predictive values of inflammatory markers were analysed with ROC curves. Results: A significant relationship was found between complications with CDC ≥ 3 and NLR, PLR, MLR, SII, and SIRI. The AUC value of SII was calculated as 0.740 (p< 0.001), NLR as 0.719 (p= 0.001), PLR as 0.668 (p= 0.011), and SIRI as 0.651 (p= 0.022). SII stands out as the marker with the highest predictive power. SII is a strong marker in predicting postoperative complications, especially in advanced-stage OC patients. Conclusions: It was shown that preoperative inflammation markers may be an effective method for predicting postoperative complications in advanced-stage OC patients undergoing CRS. These findings may contribute to optimising surgical management and reducing complications. In future studies, these markers should be evaluated in groups with more patients, and their predictive power should be investigated.
目的：肿瘤细胞减灭术（CRS）是提高晚期卵巢癌（OC）患者生存率的最重要治疗方法。然而，CRS术后并发症被视为发病率和死亡率的重要原因。患者的术前风险评估至关重要。近年来，炎症标志物已成为评估恶性肿瘤和手术结局的众多研究主题。Ca125、中性粒细胞-淋巴细胞比值（NLR）、血小板-淋巴细胞比值（PLR）、单核细胞-淋巴细胞比值（MLR）、全身炎症指数（SII）和全身炎症反应指数（SIRI）作为恶性肿瘤的预后和预测工具脱颖而出。本研究旨在评估接受CRS治疗的晚期上皮性卵巢癌患者的术前炎症标志物，并探讨其对术后并发症的预测能力。 材料与方法：这项回顾性研究纳入了2014年至2023年间在萨卡里亚大学培训与研究医院因晚期上皮性卵巢癌接受CRS的患者。患者的术后并发症根据Clavien-Dindo分级（CDC）进行分级；利用术前实验室数据计算Ca125、NLR、PLR、SII、SIRI和MLR值，并通过ROC曲线分析炎症标志物的预测价值。 结果：研究发现CDC ≥ 3级的并发症与NLR、PLR、MLR、SII和SIRI之间存在显著相关性。SII的AUC值计算为0.740（p < 0.001），NLR为0.719（p = 0.001），PLR为0.668（p = 0.011），SIRI为0.651（p = 0.022）。SII是预测能力最强的标志物。SII是预测术后并发症，尤其是晚期卵巢癌患者术后并发症的强有力标志物。 结论：研究表明，术前炎症标志物可能是预测接受CRS的晚期卵巢癌患者术后并发症的有效方法。这些发现可能有助于优化手术管理并减少并发症。在未来的研究中，应在更大患者群体中评估这些标志物，并进一步研究其预测能力。
肿瘤(癌症)患者之家